chang li
University of Washington
Seattle, United States
Associate Editor
Cancer Molecular Targets and Therapeutics
University of Washington
Seattle, United States
Associate Editor
Cancer Molecular Targets and Therapeutics
George Mason University
Fairfax, United States
Associate Editor
Cancer Molecular Targets and Therapeutics
Indian Institute of Integrative Medicine (CSIR)
Jammu, India
Associate Editor
Cancer Molecular Targets and Therapeutics
University of Naples Federico II
Naples, Italy
Associate Editor
Cancer Molecular Targets and Therapeutics
Mario Negri Institute for Pharmacological Research (IRCCS)
Milano, Italy
Associate Editor
Cancer Molecular Targets and Therapeutics
National Center for Drug Research and Evaluation, National Institute of Health (ISS)
Rome, Italy
Associate Editor
Cancer Molecular Targets and Therapeutics
Tufts Medical Center
Boston, United States
Associate Editor
Cancer Molecular Targets and Therapeutics
The University of Iowa
Iowa City, United States
Associate Editor
Cancer Molecular Targets and Therapeutics
Michigan Medicine, University of Michigan
Ann Arbor, United States
Associate Editor
Cancer Molecular Targets and Therapeutics
Department of Neuroscience, San Luigi Gonzaga University Hospital
Turin, Italy
Associate Editor
Cancer Molecular Targets and Therapeutics
Arizona State University
Tempe, United States
Associate Editor
Cancer Molecular Targets and Therapeutics
Kindai University
Higashi-osaka, Japan
Associate Editor
Cancer Molecular Targets and Therapeutics
Faculté de Médecine, Aix Marseille Université
Marseille, France
Associate Editor
Cancer Molecular Targets and Therapeutics
Warren Alpert Medical School, Brown University
Providence, United States
Associate Editor
Cancer Molecular Targets and Therapeutics
European University Cyprus
Engomi, Cyprus
Associate Editor
Cancer Molecular Targets and Therapeutics
University of Birmingham
Birmingham, United Kingdom
Associate Editor
Cancer Molecular Targets and Therapeutics